Journal News

Gut microbiome shaped by dietary sphingolipids

Nivedita Uday Hegdekar
Sept. 22, 2020

The gut microbiome comprises trillions of symbiotic micro-organisms that reside in our gastrointestinal tract and perform biochemical functions that affect metabolic health. Each individual’s microbiome is unique, and microbiome imbalance is associated with disorders such as inflammatory bowel disease and celiac disease.

Diet influences gut microbiome composition, and researchers have found that macronutrients such as carbohydrates, protein and fats are key mediators of this influence. Lipids are a major macronutrient, yet scientists know little about how individual classes of dietary lipids interact with the microbiome. 

Elizabeth Johnson studies sphingolipids, a class of lipids that consist of a sphingoid backbone attached to a fatty acid via an amide bond. Sphingolipids not only are present in most foods and synthesized from scratch by the host tissue but also are produced by gut microbes themselves. This raises some questions: How do dietary sphingolipids interact with the micro-organisms that do and do not produce sphingolipids? Are they assimilated into the microbiome? If so, how do they influence microbial metabolism?

The Johnson lab developed a methodology called bio-orthogonal labeling-sort-seq-spec, or BOSSS, for identification and fate-mapping of dietary sphingolipids in the gut microbiome. Sphingolipids were synthesized with an alkyne tag, making them distinguishable from the body’s sphingolipids and those in the host microbiome. The researchers fed the tagged sphingolipids to mice and conjugated fluorescent dyes to the tagged metabolites using click chemistry. They used fluorescence-activated cell sorting to isolate microbes that took up the alkyne-tagged sphingolipid metabolites and those that did not and further identified them using 16S rRNA gene sequencing.

Journal-news-figure-890x462.jpg
Johnson et al./JLR
This image illustrates the identification of the sphingolipid interactors of the microbiome. The bar graphs on the left show the relative abundance at the genus level, with the focused bar chart elucidating the microbial diversity of the minor fraction (1%) of the sphingolipid-interacting fraction. The microbiome members have been sorted in decreasing order of relative abundance.

The team found that the dietary sphingolipids largely were taken up by Bacteroides and Prevotella spp., two key players in the human gut microbiome. Metabolomic analysis of the microbiome of the experimental mice revealed that non–sphingolipid-producing microbes such as Bifidobacterium, a major microbiome component, could process the sphingolipids in ways similar to the sphingolipid-producing microbes such as Bacteroides and also in unique ways.

Because the foods we eat are assimilated by our microbiomes, this work could have consequences for health and, more importantly, in development of the infant microbiome. Sphingolipids comprise approximately 0.2% to 1% of the total lipids in human milk. In breastfed infants, human milk and microbiome development are intimately related during the first six months of life. As the key interactors of dietary sphingolipids are also major components of a healthy microbiome, Johnson and her group hypothesize that sphingolipids in milk could influence positively the development of the infant microbiome.

Min-Ting, first author on the paper published in the Journal of Lipid Research, looks forward to following up on their recent findings.

“We will next investigate the molecular consequences of sphingolipid consumption in infants and in our mouse models,” she said. “Furthermore, we will be using our BOSSS methodology to investigate how other lipids, for instance cholesterol, can shape the microbiome.”

Johnson believes such work has implications for microbiome-related nutrition.

“We hope other researchers studying nutrition can apply our technique to their own research,” she said. “By determining how the microbiome might be interacting with different metabolites, we can ultimately use diet to positively influence our microbiome composition. This way we can really revolutionize the field of precision medicine.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Nivedita Uday Hegdekar

Nivedita Uday Hegdekar is a recent Ph.D. graduate in biochemistry and molecular biology from the University of Maryland, Baltimore.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

What’s in a diagnosis?
Essay

What’s in a diagnosis?

Sept. 4, 2025

When Jessica Foglio’s son Ben was first diagnosed with cerebral palsy, the label didn’t feel right. Whole exome sequencing revealed a rare disorder called Salla disease. Now Jessica is building community and driving research for answers.

Peer through a window to the future of science
Annual Meeting

Peer through a window to the future of science

Sept. 3, 2025

Aaron Hoskins of the University of Wisconsin–Madison and Sandra Gabelli of Merck, co-chairs of the 2026 ASBMB annual meeting, to be held March 7–10, explain how this gathering will inspire new ideas and drive progress in molecular life sciences.

Glow-based assay sheds light on disease-causing mutations
Journal News

Glow-based assay sheds light on disease-causing mutations

Sept. 2, 2025

University of Michigan researchers create a way to screen protein structure changes caused by mutations that may lead to new rare disease therapeutics.

How signals shape DNA via gene regulation
Journal News

How signals shape DNA via gene regulation

Aug. 19, 2025

A new chromatin isolation technique reveals how signaling pathways reshape DNA-bound proteins, offering insight into potential targets for precision therapies. Read more about this recent MCP paper.

A game changer in cancer kinase target profiling
Journal News

A game changer in cancer kinase target profiling

Aug. 19, 2025

A new phosphonate-tagging method improves kinase inhibitor profiling, revealing off-target effects and paving the way for safer, more precise cancer therapies tailored to individual patients. Read more about this recent MCP paper.

How scientists identified a new neuromuscular disease
Feature

How scientists identified a new neuromuscular disease

Aug. 14, 2025

NIH researchers discover Morimoto–Ryu–Malicdan syndrome, after finding shared symptoms and RFC4 gene variants in nine patients, offering hope for faster diagnosis and future treatments.